MARKET

LPCN

LPCN

Lipocine Inc
NASDAQ
3.900
+0.040
+1.04%
Opening 10:42 02/27 EST
OPEN
3.860
PREV CLOSE
3.860
HIGH
3.932
LOW
3.860
VOLUME
7.38K
TURNOVER
0
52 WEEK HIGH
8.33
52 WEEK LOW
2.310
MARKET CAP
20.73M
P/E (TTM)
-1.2587
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at LPCN last week (0219-0223)?
Weekly Report · 1d ago
Weekly Report: what happened at LPCN last week (0212-0216)?
Weekly Report · 02/19 09:42
Lipocine Announces Key Study Dosing for Postpartum Depression Treatment
TipRanks · 02/12 21:24
Weekly Report: what happened at LPCN last week (0205-0209)?
Weekly Report · 02/12 09:38
Lipocine Announces Confirmation Of Dosing Regimen For Pivotal Study Of LPCN 1154
Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK study On track for Q2-24 pivotal study topline results and planned Q4-24 NDA filing. LPCN 1154 is an oral neurosteroid being developed by Lipocine for the treatment of postpartum depression.
Benzinga · 02/06 13:02
Weekly Report: what happened at LPCN last week (0129-0202)?
Weekly Report · 02/05 09:41
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Elevai Labs (NASDAQ:ELAB) stock is rocketing more than 76% alongside heavy pre-market trading. A private placement, direct listing, earnings reports, a public offering and more are moving stocks this morning. Check out the biggest pre- market stock movers for Thursday morning.
Investorplace · 02/01 12:38
Weekly Report: what happened at LPCN last week (0122-0126)?
Weekly Report · 01/29 09:38
More
About LPCN
Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on leveraging its Lip’ral platform to develop differentiated products through oral delivery. It has a portfolio of differentiated product candidates that target high unmet needs for neurological and psychiatric Central Nervous System (CNS) disorders, liver diseases, and hormone supplementation for men and women. The Company's product candidate, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). Its clinical development pipeline candidates include LPCN 1154 for postpartum depression (PPD), LPCN 2101 for epilepsy, and LPCN 1148 an androgen therapy for the management of cirrhosis. The Company is focused on exploring partnering opportunities for LPCN 1107, its candidate for the prevention of preterm birth; LPCN 1148, for the management of decompensated cirrhosis; LPCN 1144, its candidate for the treatment of non-cirrhotic NASH, and LPCN 1111.

Webull offers Lipocine Inc stock information, including NASDAQ: LPCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPCN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LPCN stock methods without spending real money on the virtual paper trading platform.